| In millions, except per share items | Dec-31-22 | Jun-30-21 | Dec-31-20 | Jun-30-20 | Dec-31-19 | Jun-30-19 | Dec-31-18 |
| | 10-K | 8-K | 10-K/A | 8-K | 10-K/A | 8-K | 10-K/A |
| Revenues: |
| Medical | 271.7 | | | | | | |
| United States | 429.6 | | | | | | |
| France | 142.1 | | | | | | |
| Industrial | 446.1 | | | | | | |
| Total revenues [+] | 717.8 | 611.6 | 0.0 | 478.2 | 0.0 | 440.1 | 0.0 |
| Products | | 459.3 | | 353.0 | | 325.7 | |
| Services | | 152.3 | | 125.2 | | 114.4 | |
| Revenue growth | | 27.9% | | 8.7% | | | |
| Cost of goods sold [+] | 407.7 | 359.8 | 0.0 | 281.2 | 0.0 | 251.9 | 0.0 |
| Cost of product sales | | 284.1 | | 216.8 | | 190.7 | |
| Cost of services | | 75.7 | | 64.4 | | 61.2 | |
| Gross profit | 310.1 | 251.8 | 0.0 | 197.0 | 0.0 | 188.2 | 0.0 |
| Gross margin | 43.2% | 41.2% | | 41.2% | | 42.8% | |
| Selling, general and administrative [+] | 362.3 | 211.2 | 2.4 | 158.1 | 0.0 | 145.4 | |
| General and administrative | | | 2.4 | | 0.0 | | 0.0 |
| Research and development | 30.3 | 29.4 | | 15.9 | | 14.0 | |
| Other operating expenses | | | 86.3 | | | | |
| EBITDA [+] | 92.0 | 94.8 | | 91.4 | | 98.3 | |
| EBITDA growth | | 3.7% | 26019722.9% | -7.0% | | | |
| EBITDA margin | 12.8% | 15.5% | | 19.1% | | 22.3% | |
| Depreciation and amortization | 174.5 | 83.6 | | 68.4 | | 69.5 | |
| EBIT [+] | -82.5 | 11.2 | -88.7 | 23.0 | 0.0 | 28.8 | 0.0 |
| EBIT growth | | -51.3% | 26019722.9% | -20.1% | | | |
| EBIT margin | -11.5% | 1.8% | | 4.8% | | 6.5% | |
| Non-recurring items [+] | 215.3 | | | | | | |
| Asset impairment | 215.3 | | | | | | |
| Interest income | | | 0.1 | | | | |
| Interest income | | | 0.1 | | | | |
| Other income (expense), net [+] | -8.8 | -175.5 | 43.1 | -147.6 | | -155.0 | |
| Gain (loss) on debt retirement | | | | | | 12.8 | |
| Gain (loss) on foreign currency transactions | 4.9 | | | | | | |
| Change in fair value of warrants | -37.6 | | -43.1 | | | | |
| Other | 0.4 | 1.1 | | 1.0 | | -1.9 | |
| Pre-tax income | -306.6 | -164.3 | -45.5 | -124.6 | 0.0 | -126.2 | 0.0 |
| Income taxes | -18.2 | -5.9 | -0.3 | -5.5 | 0.0 | -4.2 | 0.0 |
| Tax rate | 5.9% | 3.6% | 0.6% | 4.4% | 0.0% | 3.3% | |
| Minority interest | -11.5 | | | | | | |
| Net income | -276.9 | -158.4 | -45.3 | -119.1 | 0.0 | -122.0 | 0.0 |
| Net margin | -38.6% | -25.9% | | -24.9% | | -27.7% | |
| |
| Basic EPS [+] | ($1.53) | ($24.19) | ($0.79) | ($18.46) | $0.00 | ($19.37) | |
| Growth | | 31.0% | 4686050.9% | -4.7% | | | |
| Diluted EPS [+] | ($1.53) | ($24.19) | ($0.79) | ($18.46) | $0.00 | ($19.37) | |
| Growth | | 31.0% | 4686050.9% | -4.7% | | | |
| |
| Shares outstanding (basic) [+] | 181.1 | 6.5 | 57.0 | 6.5 | 20.1 | 6.3 | |
| Growth | | 1.5% | 183.2% | 2.4% | | | |
| Shares outstanding (diluted) [+] | 181.1 | 6.5 | 57.0 | 6.5 | 20.1 | 6.3 | |
| Growth | | 1.5% | 183.2% | 2.4% | | | |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |